Structure Therapeutics Inc. (NASDAQ: GPCR) announced the publication of Phase 2b clinical trial results for its obesity treatment aleniglipron in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE